Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Csl Ltd Sp/Adr (OP:CSLLY)

53.55 -3.27 (-5.75%)
Streaming Delayed Price Updated: 1:24 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Csl Ltd Sp/Adr

< Previous 1 2 Next >
News headline image
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗
 
Via Benzinga
News headline image
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗
 
Via Benzinga
News headline image
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines ↗
 
Via Benzinga
News headline image
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks ↗
 
Via Benzinga
News headline image
Why CSL Ltd Stock Could Be Worth a Look
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment. 
Via MarketBeat
News headline image
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗
 
Via Benzinga
News headline image
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? ↗
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology. 
Via InvestorPlace
News headline image
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗
 
Via Benzinga
News headline image
Finalization of Vifor Pharma acquisition
From Vifor Pharma AG
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021 ↗
Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.